Posted 28 August 2012 - 08:25 PM
Posted 29 August 2012 - 10:43 AM
I found the following abstract to a study that was done on lurasidone, which is the generic name for Latuda. What it says that's relevant to depression is that the medication has demonstrated antidepressant effects in animal models of depression. As far as I know, human studies pertaining to the antidepressant potential of Latuda/lurasidone are lacking at this time, but some studies may be under way. As the abstract below also states, Latuda/lurasidone is a partial agonist at 5HT1A receptors, which is a mechanism that Abilify shares and that may also produce antidepressant effects. So, there is some reason to think that Latuda may have antidepressant properties, but I can't personally vouch for its effectiveness, as I haven't tried it. Maybe if somebody here has tried Latuda, they'll chime in.
Good luck with Latuda, and welcome to Depression Forums!
J Pharmacol Exp Ther. 2010 Jul;334(1):171-81. Epub 2010 Apr 19.
Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M.
Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Suita, Osaka, Japan.
Lurasidone [(3aR,4S,7R,7aS)-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl]hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; SM-13496] is an azapirone derivative and a novel antipsychotic candidate. The objective of the current studies was to investigate the in vitro and in vivo pharmacological properties of lurasidone. Receptor binding affinities of lurasidone and several antipsychotic drugs were tested under comparable assay conditions using cloned human receptors or membrane fractions prepared from animal tissue. Lurasidone was found to have potent binding affinity for dopamine D(2), 5-hydroxytryptamine 2A (5-HT(2A)), 5-HT(7), 5-HT(1A), and noradrenaline alpha(2C) receptors. Affinity for noradrenaline alpha(1), alpha(2A), and 5-HT(2C) receptors was weak, whereas affinity for histamine H(1) and muscarinic acetylcholine receptors was negligible. In vitro functional assays demonstrated that lurasidone acts as an antagonist at D(2) and 5-HT(7) receptors and as a partial agonist at the 5-HT(1A) receptor subtype. Lurasidone showed potent effects predictive of antipsychotic activity, such as inhibition of methamphetamine-induced hyperactivity and apomorphine-induced stereotyped behavior in rats, similar to other antipsychotics. Furthermore, lurasidone had only weak extrapyramidal effects in rodent models. In animal models of anxiety disorders and depression, treatment with lurasidone was associated with significant improvement. Lurasidone showed a preferential effect on the frontal cortex (versus striatum) in increasing dopamine turnover. Anti-alpha(1)-noradrenergic, anticholinergic, and central nervous system (CNS) depressant actions of lurasidone were also very weak. These results demonstrate that lurasidone possesses antipsychotic activity and antidepressant- or anxiolytic-like effects with potentially reduced liability for extrapyramidal and CNS depressant side effects.
[PubMed - indexed for MEDLINE]
Has long-standing difficulties with energy and concentration, as well as perceptual and cognitive problems
Taking Abilify & supplements including vitamins B3 & D3
0 user(s) are reading this topic
0 members, 0 guests, 0 anonymous users